Cyto Pulse, Karolinska Institutet get clinical trial approval

GLEN BURNIE, Md. — Cyto Pulse Sciences announced Feb. 22 approval from the Swedish Medical Products Agency to conduct a phase I clinical trial evaluating an HIV/DNA vaccine in collaboration with the Karolinska Institutet and the Swedish Institute for Infectious Disease Control.

Cyto Pulse Sciences produces electric field—based, intradermal DNA vaccine delivery systems.

The vaccine will be delivered to healthy volunteers by ZetaJet, a needle-free injection system from Bioject Medical Technologies Inc., in combination with Cyto Pulse’s intradermal electroporation system Derma Vax.

The study will be sponsored by the Swedish institute and conducted at the Karolinska Institutet. They developed the multivalent HIV vaccine.

The combination of intradermal injection by ZetaJet and electroporation by Derma Vax is thought to broaden the response of the vaccine.